Category: News

Join CESPE as our Operational Manager!

Are you ready to play a pivotal role in shaping the future of pharmaceutical engineering and manufacturing? The Centre of Excellence in Sustainable Pharmaceutical Engineering & Manufacturing (CESPE) at Ghent University is seeking an Operational Manager to drive our ambitious goals forward.

Your Mission

CESPE, a collaboration between 19 research groups at Ghent University Association and industrial partners, aims to lead the way in sustainable pharmaceutical manufacturing innovations. As our Operational Manager, you will work closely with the CESPE Director, General Manager, Project Manager, and Business Developers to support our objectives and diverse range of activities.

Key Responsibilities

• Collaborate with the team to develop a future-proof operational strategy for the CESPE Innovation Accelerator.
• Translate research activities and expectations into technical specifications for the design and construction of the Innovation Accelerator.
• Proactively develop a training program that meets the needs of our industrial partners.
• Contribute to the expansion of the project portfolio in collaboration with researchers and partner companies.
• Facilitate interactions with industrial partners and maintain continuity in partnerships.
• Enhance CESPE’s visibility through representation at international conferences, event organization, and communication campaigns.

Your Profile

• Master’s or Ph.D. degree in (bio-)engineering, pharmaceutical sciences, veterinary medicine, or equivalent.
• Strong knowledge and interest in scientific domains within CESPE.
• Proficient in project management, with excellent organizational skills and a focus on timely execution within budget.
• Experience or knowledge of technical requirements in a high-tech pharmaceutical production environment is advantageous.
• Passionate about building a world-class expertise center in sustainable pharmaceutical production.
• Familiarity with the workings of universities and industrial actors such as pharmaceutical companies (relevant network preferred).
• Experience in developing public-private project proposals is a plus.
• Excellent communication skills in English and Dutch, both verbal and written.
• A team player who can work independently and efficiently in a complex organization with a “get things done” attitude.

What We Offer

We provide a permanent contract, offering stability and opportunity for growth within our dynamic team.

Ready to Make an Impact?

If you’re excited about contributing to the forefront of sustainable pharmaceutical engineering and manufacturing, we want to hear from you! Join us at CESPE and be part of a collaborative effort to shape the future of pharmaceutical innovation. Apply now to seize this opportunity to drive meaningful change in the industry.

Interested?

Apply through this link before the application deadline (February 22, 2024): https://jobs.ugent.be/job/Gent-Operationeel-manager-9000/786619002/

Join our Industrial Member Secoya at a two-day crystallization event!

During this event, you’ll have the exclusive opportunity to discover Secoya’s continuous crystallization technology, explore their latest technological breakthroughs, meet their experts, dive into research and industrial case studies and network with fellow enthusiasts.

Last but not least, Secoya will seize the opportunity to showcase the whole new SCT family, from lab to industrial unit.

Ghent (October 5^th, 2023) – It is with great pleasure that Pfizer Puurs and Ghent University (UGent) announce that Pfizer has officially joined the CESPE innovation cluster, a multi-partner innovation accelerator in the field of pharmaceutical engineering and manufacturing.

We are proud of our footprint in Belgium and our worldwide impact, and happy to expand it further through this collaboration with CESPE at Ghent University.
As we continue to innovate and improve our manufacturing processes and expertise, it is critical that we collaborate with the best and brightest, and we are confident the team at CESPE has the right expertise to make this partnership a great match.

Gudrun Coppens, Director Manufacturing Science & Technology at Pfizer Puurs

The close collaboration between industry and academia in this strategic partnership, combined with their drive to innovate, will play a key role in future pharmaceutical manufacturing.

We are thrilled to welcome Pfizer Puurs to our fast-growing CESPE community of leading innovators in (bio)pharmaceutical manufacturing. We are excited to embark on this inspiring collaborative journey with Pfizer Puurs . This partnership also plays a pivotal role in nurturing local talent and fostering a culture of continuous innovation reflecting the spirit of the thriving Belgian pharma/biotech ecosystem, and particularly the flourishing region of Flanders .

Dr. Dominic De Groote, Business Development Manager at CESPE

About Pfizer Puurs

Pfizer Manufacturing Belgium is the largest production and packaging site of Pfizer worldwide, specializing in aseptic production and packaging. The Pfizer Puurs facility covers 100.000m², and manufactures more than 400 million units of injectable medicines and vaccines every year (excl. Comirnaty). The product physiology ranges from sterile solutions, to sterile suspensions, sterile gels, and freeze dry products, all packed on site in ampoules, vials, plastic bottles, syringes, or cartridges for pens. The medicines and vaccines made in Puurs are shipped to patients in more than 170 markets. 30% of Puurs production is destined for low income countries, in collaboration with UNICEF, WHO, GAVI, and NGOs.

The site has an extensive manufacturing setup with a range of formulation booths, filling lines, automatic inspection lines, packaging lines, freeze driers, and lab facilities. With their clinical pilot plant and experimental plant the Pfizer Puurs is also known as a Launch Site within the Global Pfizer network, providing them the ability to quickly scale-up to commercial manufacturing of a new product.
The last 10 years the number of employees in Puurs has more than doubled, bringing the total number of employees to more than 4.500 in 2023.

For more information, visit https://www.pfizer.be.

About UGent-CESPE

Ghent University (UGent) is a top 100 university and one of the largest Belgian universities in the heart of Europe. It is an active partner in national and international educational, scientific and industrial cooperation. The organization is committed to research and innovation with an annual research budget of more than € 600 million and more than 5,500 researchers active in a wide range of the life, physical and social sciences. UGent TechTransfer and the UGent Business Development Platforms, such as CESPE, support researchers in developing groundbreaking science to bring innovations to the market.

The Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE) is a multidisciplinary innovation accelerator hosted at Ghent University focusing on the sustainable development, design and optimization of both drug substance and drug product production platforms. Its ambition is to become the reference centre in end-to-end (bio)pharmaceutical manufacturing in Europe. It accelerates the development of emerging production technologies to manufacture the medicines of the future in a sustainable, agile way.

For more information, visit https://www.cespe.be.

Media contact:

Pfizer

Koen Colpaert, spokesperson Pfizer Manufacturing Belgium
Tel.: +32 499 42 85 56

CESPE

Thomas De Beer, director and principal investigator
Tel: +32 9 264 80 97

Leading global professional services company, Cognizant, and the Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE) have today announced a partnership which will accelerate the realization of innovative, sustainable, and agile developments in the pharmaceutical sector, at large scales.

The partnership will focus on knowledge sharing and prototyping ground-breaking ideas across various industry related topics, such as industry 4.0 and maximizing the value of Digital Twins in R&D and manufacturing by hybrid modelling, with use of the latest advanced analytical methods. Cognizant will also become a CESPE Industrial Member, joining the growing community where academic researchers and industrial partners are connected and where they can exchange information on sustainable pharmaceutical engineering and manufacturing at multiple levels. 

Both Cognizant and CESPE’s main goal is to reinvent the pharmaceutical and biopharmaceutical industry: Cognizant as a technology partner and CESPE as complementary research center. CESPE is a multidisciplinary innovation accelerator hosted at Ghent University focusing on the sustainable development, design and optimization of both drug substance and drug product production platforms. Ghent University (UGent) is a top 100 university and one of the largest Belgian universities in the heart of Europe. It is an active partner in national and international educational, scientific, and industrial cooperation. CESPE’s ambition is to become the reference center in end-to-end (bio)pharmaceutical manufacturing in Europe. It accelerates the development of emerging production technologies to manufacture the medicines of the future in a sustainable, agile way. Cognizant implements, integrates, operationalizes, and scales such innovations within the life sciences industry, while contributing to similar ground-breaking innovative ideas with resourceful individuals working for Cognizant with various skills and rich domain knowledge. Conversely, CESPE can apply Cognizant’s patented technological solutions in examining and prototyping their own research.

“We at Cognizant are incredibly excited to partner with a leading institute like CESPE. Together, we are going to make significant strides in the development of technologies like digital twins in the pharmaceutical industry. This will make companies, and the overall industry, much more flexible and effective, thus stimulating innovation. We are proud to be doing our part to support the significant life sciences industry in Belgium, which has huge impact both locally and beyond.”

Gregory Verlinden, Associate Vice President of Analytics & AI at Cognizant

“We are actively looking for partnerships that endorse our core values. Cognizant’s complementary nature is exactly what we are looking for: a balanced collaboration with a reciprocal knowledge exchange. Our collaboration starts with the digital twin but can certainly expand later.”

Bram Bekaert, Operational Manager at CESPE

Find out more about Cognizant on their webpage: https://www.cognizant.com/

🌍 Join our team and shape the future of sustainable pharmaceutical engineering and manufacturing! 🚀

Are you passionate about driving innovation in the pharmaceutical industry? Do you want to be part of a world-class team working towards sustainable manufacturing solutions? Look no further!

We are recruiting a Project Manager for the Centre of Excellence in Sustainable Pharmaceutical Engineering & Manufacturing (CESPE) at Ghent University. As CESPE strives to become the reference point for sustainable pharmaceutical production innovations globally, we need an exceptional individual to help us achieve our goals.

As a Project Manager, you will collaborate closely with our dynamic team, including the CESPE Director, Managing Director, Operational Manager, and Business Developers. You will play a vital role in attracting additional funding, coordinating subsidy reporting, supporting commercialization strategies, and fostering strong relationships with stakeholders.

Join us in building a sustainable future for pharmaceutical manufacturing.
Visit our website to learn more about CESPE and our exciting initiatives.

Get more information and apply here before June 30th. 

One of the CESPE research groups (The Laboratory of Pharmaceutical Technology) is recruiting a full-time Ph.D. student in the field of continuous manufacturing of pharmaceuticals.

You will have the chance to play an important role within the domain of pharmaceutical technology, more specifically in the field of (continuous) manufacturing of pharmaceutical dosage forms.
During your Ph.D. you will get the chance to publish your research data in international peer-reviewed papers; assist in the teaching activities at the Laboratory of Pharmaceutical Technology, including the guidance of master dissertations; and assist in the internal and external services by the Laboratory of Pharmaceutical Technology.

Don’t hesitate to take a look at the vacancy.

Ghent University is now accepting applications for our Master of Science in Pharmaceutical Engineering (MPE) program. Our program offers a unique combined training of pharmaceutical and engineering skills. Both skills are required to develop these pharmaceutical production processes for tomorrow’s drug products and supply needs.
The MPE consists of a two-year English-taught programme of 120 credits and will help you acquire all skills and knowledge that you need to implement novel manufacturing concepts that require a high degree of digitalization and automation. The MPE will also increase your opportunities to get a good position in the pharmaceutical industry or to become an excellent PhD candidate!

For further information, please take a look at the MPE site: https://lnkd.in/gXFbn42H.

It is with great honour that we can announce professor Dieter Deforce as a new academic member of CESPE. His expertise in the fields of pharmaceutical biotechnology and (forensic) DNA-analysis are a crucial addition to the CESPE portfolio.

Dieter Deforce is a professor at the University of Ghent and is the head of the Laboratory of Pharmaceutical Biotechnology at the Faculty of Pharmaceutical Sciences. From 2001 till 2016 he was also head of the forensic DNA‐analysis laboratory, which he founded at the University of Ghent, accredited and recognized by the Belgian government. He remains in the forensic field as dedicated DNA expert.

He is chair of the Belgian Medicines Committee, member of the Scientific Advise Working Party of the European Medicines Agency. He is also the director of the ProGenTomics platform of the University of Ghent, providing amongst others proteomics and mainly mass spectrometry based protein analytical tools to the research community. He is a partner in NXT‐GNT, a research consortium providing the research community next generation DNA‐sequencing. He is member of the board of directors of the VIB.

His research focuses on applying proteomics and genomics platforms (including Next Generation Sequencing) in the field of post translational protein modifications, stem cell development, prenatal genetic diagnosis, (auto‐)immunity and forensics and he is (co‐)author of over 350 scientific papers.

We are excited to announce that professor Hristo Svilenov has joined CESPE as an academic member. With the onboarding of prof. Svilenov, we further strengthen our capabilities in the field of biopharmaceutical manufacturing.

Hristo Svilenov is a professor of biopharmaceutical manufacturing technology and formulation in the Laboratory of General Biochemistry and Physical Pharmacy at Ghent University. Before moving to Ghent, he was postdoc with Prof. Johannes Buchner at the Technical University of Munich funded by a fellowship from the Peter und Traudl Engelhorn Foundation and a grant from the Else Kröner-Fresenius Foundation. From 2016 to 2019, he did his PhD sponsored by a Maria Skłodowska-Curie fellowship in the group of Prof. Gerhard Winter at the University of Munich. For his research, Dr. Svilenov received several prizes like the Carl Wilhelm Scheele Award from the German Pharmaceutical Society (DPhG) or the Abbvie Award for the best doctoral thesis. He is a pharmacist by training.

Hristo Svilenov is working on different aspects of the development, manufacturing, and formulation of biotherapeutics. A strong research focus is on the application of novel analytical techniques and biophysical methods to design better therapeutic proteins and formulations.

2 PhD Positions to develop a Predictive Framework enabling Real-Time Release Testing in Solid Dosage Manufacturing

Overview

This PhD project aims to develop a knowledge-based predictive framework for dissolution testing to enable real-time release testing (RTRt) in solid dosage manufacturing. The research will be conducted in close cooperation with pharmaceutical companies and the UGent research accelerator Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE). The research outcome will be published in important scientific journals.

Traditionally, RTRt frameworks are developed by individual companies and partnering research institutions leading to a costly and resource-intensive process. Moreover, the development requires a thorough process understanding as well as controls embedded in the production processes. In this project, a predictive framework for dissolution testing will be developed using material, process, and PAT data from continuous direct compression process. This project presents a unique opportunity to work at the academia-industry interface on a very important and relevant topic to the pharmaceutical industry. A range of formulations and knowledge from multiple pharmaceutical companies involved in the project will lead to development of a generic and better predictive framework enabling RTRt.

The project currently has two open positions for PhD candidates: a PhD project with an Experimental focus and a PhD project with a mathematical modeling focus. The researcher with an experimental focus will get an in-depth scientific understanding, hands-on experience of direct compression based manufacturing and gain expertise in practical aspects of dissolution test development applicable to an industrial working environment. The researcher with a modeling focus will apply different modeling approaches of developing in vitro predictive dissolution models based on product and process understanding. Hence, a predictive dissolution modeling framework will be developed to support product development within the space explored during formulation and process optimization and as surrogate tests in a regulatory filing towards RTRt.

Profiles

Experimental research focus:

1. Master’s degree in pharmaceutical sciences, physical chemistry, or a related discipline
2. Experience in dissolution testing of pharmaceutical dosage forms.
3. Experience with various analytical techniques (DSC, XRD, IR, TGA, DVS, HPLC).
4. Experience in multivariate data analysis is desirable.

Mathematical modeling research focus:

1. Master’s degree in bioengineering, chemical engineering, and process engineering or a related discipline
2. Experience with the development of numerical methods
3. Experience with mechanistic and data-driven modeling methodologies
4. Experience in Python and/or MATLAB is desirable.
5. Candidates must have a strong interest in both experiments and theoretical modeling

More information
For further information, please contact:

Pharmaceutical engineering research group (Ghent University) Faculty of Pharmaceutical Sciences

Prof. dr. Ashish Kumar (Ashish.Kumar@UGent.be)

LPPAT research group (Ghent University) Faculty of Pharmaceutical Sciences

Prof. dr. Thomas De Beer (Thomas.DeBeer@UGent.be)

Laboratory of Pharmaceutical Technology (Ghent University) Faculty of Pharmaceutical Sciences

Prof. dr. Chris Vervaet (Chris.Vervaet@UGent.be), Prof. dr. Valérie Vanhoorne (Valerie.Vanhoorne@UGent.be)

How to apply

You have to use the online application tool available here or by sending an email to Ashish.Kumar@UGent.be to provide your CV with names of three references, motivation letter and transcripts of your bachelor and master studies.

Application deadline and start date

The position is available immediately and will remain open until it is filled. While the start date is flexible, the target is to start from Feb 2022.

2 PhD positions in Pharmaceutical Manufacturing Innovation with Focus on Continuous Pharmaceutical Freeze-Drying

Overview

The general goal of these PhD research projects is to further innovate in a continuous freeze-drying technology for (bio)pharmaceuticals and explore its potential as an enabler for different pharmaceutical products.

Topic 1: The evaluation of different energy supply systems for the continuous & controlled
(mechanistic based) freeze-drying of biopharmaceutical unit doses.

Topic 2: Continuous freeze-drying as an enabling technology for different types of pharmaceutical products (e.g., lipid nano-particle based products, highly concentrated protein formulations, vaccines, cold chain distributed products, etc.)
The research projects may be conducted in close cooperation between Ghent University (Belgium) and
pharmaceutical companies and equipment manufacturers. The PhD project will be executed in Ghent, Belgium. The research outcome will be published in important scientific journals.

Profile

1. Master’s degree in Pharmaceutical Drug Development, Industrial Pharmacy, Pharmaceutical Engineering, Bio-science Engineering, Chemical Engineering or a related discipline.
2. Experience with pharmaceutical technology is desirable.
3. Candidates must have a strong interest in biopharmaceutical product development manufacturing innovation, analysis and data-analysis.

The PhD project will be guided by the Pharmaceutical Process Analytics & Technology research group (Faculty of Pharmaceutical Sciences, Ghent University, Prof. Dr. Thomas De Beer), and will be in collaboration with the Pharmaceutical Engineering Research Group (Prof. Dr. Ashish Kumar).

Pharmaceutical Process Analytics & Technology research group (Ghent University) Faculty of Pharmaceutical Sciences
Prof. Dr. T. De Beer – Thomas.DeBeer@UGent.be – +32-9-2648097

How to apply

Please send your CV with names of three references, motivation letter and transcripts of your bachelor and master studies to Thomas.DeBeer@UGent.be

Application deadline

Please apply before February 28th, 2022

Belgium has an excellent position in the development of new medicines. ‘To continue to play that leading role, we also need to focus on innovation in drug production,’ says Professor Thomas De Beer.

With the CESPE Innovation Accelerator, Ghent University offers an answer to the need for top research infrastructure for innovation in pharmaceutical production technology. This is necessary to further anchor Belgium’s leading position in the field of drug development research and to guarantee its production in our region.

Need for innovation in pharmaceutical production

‘If you look at pharmaceutical manufacturing innovation over the last decades, it hasn’t kept up with the speed of drug development. Innovation in the pharmaceutical sector primarily focuses on the development of medicines. But the increasing complexity of medicines and their supply needs also requires innovation in production technology,’ says Professor Thomas De Beer. He is director of CESPE, the Center of Excellence for Sustainable Pharmaceutical Engineering & Manufacturing at Ghent University, which is the basis of the new innovation accelerator for production technology in the pharmaceutical sector.

‘Innovation in the pharmaceutical sector primarily focuses on the development of medicines. But the increasing complexity of medicines and their supply needs also requires innovation in production technology.’ Professor Thomas De Beer.

‘Unlike other sectors in the manufacturing industry, pharmaceutical products are often developed before it is clear how they can be produced on a large scale in a competitive, sustainable and flexible way. By linking the development of a medicine at an early stage to the development of the production process, you shorten the lead time,’ explains Professor De Beer.

‘The Corona pandemic has also increased the need for agile production technologies. Just think of the supply of intermediate substances in the event of an abruptly rising demand or local production of critical medicines, and the associated cold chain distribution at -80°C of certain vaccines. This requires new technologies and we will research and develop them in the new CESPE center in collaboration with the industry,’ says Wouter De Soete, manager of CESPE at Ghent University.

Unique research infrastructure

The CESPE Innovation Accelerator will include cleanrooms, lab and office space as well as a (bio)pharmtech incubator. ‘This combination of research infrastructure in the field of production innovation is unique in Belgium. With this we make a huge difference, not only for academic research but also for industry,’ emphasizes Professor De Beer.

‘This research infrastructure in the field of production innovation is unique in Belgium. With this we make a huge difference, not only for academic research but also for industry.’ Professor De Beer.

There are strict requirements for the production of medicines. You have to create the right conditions for researchers and for the products you work with. Thanks to the modular and flexible layout of the cleanrooms and lab areas, large companies, start-ups and research institutions can perform tests and collaborate under optimal conditions. This is the only way to create the right environment for innovation.’

The center also provides the necessary space to accommodate spin-offs resulting from this innovative research. ‘We strongly believe that cross-fertilization between industry and academia will lead to innovative production technologies. In the field of production technology within the pharmaceutical sector, we want to become the reference point, both for research and training of the right profiles. For that reason, we will start with a new master in pharmaceutical engineering in the academic year 2022-2023. This combination of pharmaceutical and engineering skills is much needed in the sector to realize innovation. By focusing on that, we are firmly convinced that this will lead to new start-ups. We also want to offer them the necessary support in the CESPE center to start up and grow.’

‘The main goal of CESPE is to be the leading innovation hub in Europe for the end-to-end pharmaceutical production of tomorrow’s medicines,’ according to Wouter De Soete. ‘That means that we examine the entire drug production chain, from development to its supply to the market, and examine how we can model and optimize it as best as possible. For this we have to call on different expertise. Just think of experts in the field of big data, AI, automation and robotization, energy-efficient production,…’ According to De Soete, the center in Zwijnaarde will be a game changer for the pharmaceutical industry in Flanders, which will also provide a lot of jobs.

More information

Thomas De Beer, thomas.debeer@ugent.be

Wouter De Soete, wouter.desoete@ugent.be

Ghent (March 25, 2021) – Takeda and Ghent University (UGent) are pleased to announce that Takeda’s Global Manufacturing Site at Lessines has officially joined the CESPE innovation cluster, a multi-partner innovation accelerator in the field of pharmaceutical engineering and manufacturing. This strategic partnership reflects both parties’ strong desire to further intensify their research and innovation efforts and to make optimal use of the cross pollination between industry and academia. Initially, this partnership will focus on optimising digitization in Pharma 4.0, pharmaceutical technology innovation, and optimising energy and material efficiency during production.

“As one of the global leaders in the production of plasma derivatives, Takeda continuously improves its manufacturing operations. To this end, the mutual sharing of knowledge with other companies and knowledge institutions like CESPE is key”, says Gert Verheyden, Head of Manufacturing Sciences at Takeda Lessines. “This allows Takeda Lessines to make a significant contribution to the training of tomorrow’s pharmaceutical engineers, both in existing and emerging education tracks, and also to increase the industrial relevance of possible innovation projects at the international level.” “We are thrilled to collaborate with Takeda and to thus facilitate its strong desire to implementing innovative production processes of active pharmaceutical ingredients and finished pharmaceutical products. We are collaborating precompetitively with an industrial network to build a strong knowledge region enabling the local anchoring of talent and innovation”, says professor Thomas De Beer, Director of CESPE.

 About Takeda

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.

Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit https://www.takeda.com.

About UGent-CESPE

Ghent University (UGent) is a top 100 university and one of the largest Belgian universities in the heart of Europe. It is an active partner in national and international educational, scientific and industrial cooperation. The organization is committed to research and innovation with an annual research budget of more than € 600 million and more than 5,500 researchers active in a wide range of the life, physical and social sciences. UGent TechTransfer and the UGent Business Development Platforms, such as CESPE, support researchers in developing groundbreaking science to bring innovations to the market.

The Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE) is a multidisciplinary innovation accelerator hosted at Ghent University focusing on the sustainable development, design and optimization of both drug substance and drug product production platforms. Its ambition is to become the reference centre in end-to-end (bio)pharmaceutical manufacturing in Europe. It accelerates the development of emerging production technologies to manufacture the medicines of the future in a sustainable, agile way.

For more information, visit https://www.cespe.be.

Media Contact:

Takeda:
Stefaan Fiers, Head of Corporate Communication
Tel: 0476 76 90 77

CESPE:
Wouter De Soete, Manager
Tel: 0474 80 65 67

Great job opportunity! Want to develop your Process Development Engineering skills? Our partner simAbs, developing a new biopharmaceutical manufacturing platform, might have just the challenge you’re looking for! Check out the job offer here!

SUSTAINABLE PHARMACEUTICAL MANUFACTURING INNOVATION

SAVE THE DATE for the first CESPE Industrial Partnering Day!
December 2nd, 2.00pm – 5.00pm
Feel free to forward within your organisation 

Interested in how Ghent University accelerates innovation and cultivates partnerships in Sustainable Pharmaceutical Engineering and Manufacturing? Innovating in the pharmaceutical or biotech industry? Equipment, infrastructure developer or system integrator? We gladly introduce you to CESPE and provide you with a selection of high-quality R&I pitches from both UGent and industry!

Speakers:

• UGent rector Rik Van de Walle
• Deputy mayor of the City of Ghent Sofie Bracke
• World class industry leaders: Janssen Pharmaceutica and Takeda.

Register now to receive your personal invite and program updates on the Keynote and pitching sessions!

Free of charge. Registration is closed.

End-to-end integrated pharmaceutical manufacturability of tomorrow’s medicines – Enabling sustainable innovation in drug substance and drug product production.

Fascinated by pharmaceutical process development and how novel drug manufacturing techniques contribute to that? Eager to pursue a PhD in Pharmaceutical Sciences on the industrial implementation of continuous tablet manufacturing via direct compression?

This could be your opportunity! A collaboration between Ghent University CESPE and Johnson and Johnson Belgium!

More information on the topic and how to apply on the UGent Job portal!

Short project description

The pharmaceutical industry is switching from batch-wise to continuous manufacturing of tablets. The aim of current project is to address crucial gaps of knowledge for industrial implementation of continuous tablet manufacturing via direct compression.

During drug product development limited amounts of new chemical entities are available to investigate the effect of formulation and process variables on the final drug product. The first aim is therefore to develop a strategy for identification of a surrogate component, i.e. a component with similar characteristics as the new chemical entity, to use during early process and formulation development trials. Furthermore, continuous feeding of very cohesive raw materials is often challenging and affects further downstream processing. Therefore, various formulation strategies to overcome feeding issues of very cohesive raw materials in function of process parameters will be developed. Finally, a control strategy based on residence time distributions is of utmost importance to ensure the final product quality and traceability along the manufacturing line. Therefore, the critical formulation and process parameters affecting residence time distributions on a continuous direct compression line will be investigated and predictive models will be built for each unit operation and for the integrated line.

Interested in the capabilities of continuous freeze-drying? What is the impact on stability, supply chain, manufacturing operations, quality control, etc.?

Subscribe to the hands-on workshop on batch versus continuous freeze-drying of pharmaceuticals!

• Demonstration of continuous freeze-drying prototypeF
• Formulation characterization for batch and continuous freeze-drying hands-on training
• DEMO PAT for continuous freeze-drying
• Dynamic design space determination
• Execution of batch and continuous freeze-drying processes for selected formulations
• Evaluation performed batch and continuous freeze drying runs
• Determination CQAs freeze-dried products: batch versus continuous

CESPE will present to you at Knowledge for Growth 2018 this week Thursday 17th in Ghent #KfG2018! Visit us at exhibition booth 75, first floor of TTO Flanders Ghent University Tech Transfer to get to know more about the Centre of Excellence in Sustainable Pharmaceutical Engineering. #KfG2018 with flanders.bio. https://www.knowledgeforgrowth.be/